GCM
TAK icon

Glenview Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Glenview Capital Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,102,119
Closed -$133M – 64
2021
Q3 		$133M Sell
8,102,119
-1,013,402
-11% -$17M 2.41% 11
2021
Q2 		$153M Sell
9,115,521
-6,988,701
-43% -$119M 2.54% 9
2021
Q1 		$294M Buy
16,104,222
+843,710
+6% +$15.2M 4.98% 6
2020
Q4 		$278M Sell
15,260,512
-1,528,077
-9% -$26.8M 6.37% 3
2020
Q3 		$300M Buy
16,788,589
+593,279
+4% +$10.8M 9.4% 2
2020
Q2 		$290M Sell
16,195,310
-3,761,689
-19% -$67.5M 8.01% 2
2020
Q1 		$303M Sell
19,956,999
-10,625,722
-35% -$193M 8.24% 1
2019
Q4 		$603M Buy
30,582,721
+3,138,875
+11% +$60.1M 5.28% 5
2019
Q3 		$472M Buy
27,443,846
+1,013,018
+4% +$17.5M 4.97% 5
2019
Q2 		$468M Buy
26,430,828
+318,168
+1% +$5.79M 4.24% 8
2019
Q1 		$532M Buy
+26,112,660
New +$525M 4.75% 7

Other funds holding TAK

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Glenview Capital Management's TAK Position: Q4 2021 in Review

Glenview Capital Management sold out of Takeda Pharmaceutical (TAK) in Q4 2021, closing a stake of 8,102,119 shares — an estimated $133M sold.

Glenview Capital Management first reported a position in TAK in Q1 2019 and held it in 11 quarters. The position peaked at $603M in Q4 2019. 298 funds tracked by Wall St. Rank hold TAK as of Q4 2021.

  • Glenview Capital Management reported no remaining Takeda Pharmaceutical position as of Q4 2021 after selling out during the quarter.
  • Glenview Capital Management sold 8,102,119 Takeda Pharmaceutical shares in Q4 2021, an estimated $133M.
  • Glenview Capital Management first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 11 quarters.
  • Glenview Capital Management's Takeda Pharmaceutical position peaked at $603M in Q4 2019.
  • 298 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2021.

Based on Glenview Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.